Chikungunya with UTMB's Scott Weaver

Researchers have developed a new candidate vaccine to protect against chikungunya virus, a mosquito-borne pathogen that produces an intensely painful and often chronic arthritic disease that has stricken millions of people in India, Southeast Asia and Africa.


UTMB has signed a license agreement with Inviragen for commercialization of the new vaccine candidate. In addition, the two partners have been chosen to receive a four-year, $3 million grant from the National Institutes of Health to complete the preclinical development work needed submit an investigational new drug application to the Food and Drug Administration, opening the door to human trials.

Category:

Education

Tags:

• UTMB
• Health
• Chikungunya
• Dengue
• Galveston
• Houston
• Dallas
• San
• Antonio
• Austin
• Texas
• Hospital
• University
• Research
• Infectious
• Diseases
• Hemorrhagic
• Fever
• Mosquito
• Vector